Security

Class

Title

Amount to

be

Registered(1)

Proposed

Maximum
Aggregate

Offering

Price

Fee

Rate

2019 Equity Incentive

Plan (Common stock,

$0.0001 par value per share)

457(c)

and

457(h)

2019 Employee Stock

Purchase Plan (Common

stock, $0.0001 par value

per share)

457(c)

and

457(h)

2022 Inducement Plan

(Common stock, $0.0001

par value per share)

457(c)

and

457(h)

Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of common stock that become issuable under the above-named plans by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of Harpoon Therapeutics, Inc.’s (the “Registrant”) outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).

Represents additional shares of the Registrant’s Common Stock reserved for future grant under the Harpoon Therapeutics, Inc. 2019 Equity Incentive Plan (the “2019 Plan”) as a result of the automatic increase in shares reserved thereunder on January 1, 2024 pursuant to the terms of the 2019 Plan. The 2019 Plan provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the 2019 Plan beginning on January 1, 2019 and ending on (and including) January 1, 2029 in an amount equal to the lesser of (a) 5% of the total number of shares of the Registrant’s capital stock outstanding on December 31st of the preceding calendar year and (b) a number of shares of Common Stock designated by action of the Registrant’s board of directors prior to the first day of any calendar year.

Represents additional shares of the Registrant’s Common Stock reserved for issuance under the Harpoon Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the “ESPP”) as a result of the automatic increase in shares reserved thereunder on January 1, 2024 pursuant to the terms of the ESPP. The ESPP provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the ESPP beginning on January 1, 2019 and ending on (and including) January 1, 2029. The number of shares added each year will be equal to the lesser of: (a) 1% of the total number of shares of the Registrant’s capital stock outstanding on December 31st of the preceding calendar year; (b) 750,000 shares of Common Stock and (c) a number of shares of Common Stock designated by action of the Registrant’s board of directors prior to the first day of any calendar year.

Represents additional shares of the Registrant’s Common Stock reserved for issuance pursuant to stock awards that may be granted under the Harpoon Therapeutics, Inc. 2022 Inducement Plan as inducement grants under Nasdaq Listing Rule 5635(c)(4).

Estimated pursuant to Rule 457(c) and Rule 457(h) solely for the purpose of calculating the registration fee on the basis of $11.41 per share, which is the average of the high and low prices of the Common Stock as reported on The Nasdaq Global Select Market on January 2, 2024, rounded up to the nearest cent.

Estimated pursuant to Rule 457(c) and Rule 457(h) solely for the purpose of calculating the registration fee on the basis of $9.70 per share, which is 85% of the average of the high and low prices of the Common Stock as reported on The Nasdaq Global Select Market on January 2, 2024, rounded up to the nearest cent.